+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Peptide Antibiotics Market Size, Share & Trends Analysis Report By Disease (Skin Infection, HABP/VABP), By Route of Administration (Injectable, Oral), By Product, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • January 2025
  • Region: Global
  • Grand View Research
  • ID: 5644997
The global peptide antibiotics market size is estimated to reach USD 6.64 billion by 2030, expanding at a CAGR of 5.1% from 2025 to 2030. The market is expected to witness growth opportunities owing to factors such as the increasing research and development activities in field of peptide antibiotics coupled with high number of drug approvals. Moreover, surge in cases of antimicrobial resistance cases and possibility of side effects from the conventional antibiotics are also expected to drive the market during the forecast period.

Increasing prevalence of cancer and other infectious diseases are expected to propel the growth over the forecast period. For instance, according to the CDC, United States reported 1,752,735 new cancer cases along with 599,589 deaths in 2019. For every 100,000 people, 439 new cases were found and 146 people died due to cancer. Further, according to Globocan 2020, U.K. had 457,960 new cases with 179,648 deaths in 2020. The most common types of malignancies were breast, prostate cancer and Non-Hodgkin’s lymphoma.

There are some of the peptide antibiotics which are used to treat cancers such as, NHL, Hodgkin’s lymphoma, and certain types of skin malignancies. According to Globocan 2020, there were 5,44,352 Non-Hodgkin lymphoma cases and 83,087 Hodgkin’s lymphoma cases. The efficiency of various existing products is expected to result into higher revenues owing to doctor recommendations . For instance, BLEOMYCIN for injection USP is the mixture of cytotoxic glycopeptide antibiotics that is isolated from Streptomyces verticillus and is used for the treatment of testicular carcinoma, squamous cell carcinoma, and various types of lymphomas.

Moreover, ongoing product approvals and strategic initiatives undertaken by market players such as partnerships, collaborations, product launches, and expansions are expected to fuel market growth during forecast period. For instance, in July 2021, AbbVie Inc announced that the U.S. FDA approved DALVANCE for the treatment of acute bacterial skin and skin structure infections in pediatric patients from birth. Moreover, in July 2020, Sandoz International GmbH announced introduction of Daptomycin injection 500 mg, a generic version of Cubicin, in the U.S. market for the treatment of adult patients with complicated skin and skin structure infections and several type of bloodstream infections.

Peptide Antibiotics Market Report Highlights

  • The non-ribosomal synthesized peptide antibiotics segment dominated the market and accounted for 72.79% of the global revenue in 2024.
  • The hospital pharmacies segment dominated the market with a market share of 43.96% in 2024.
  • Asia Pacific region is expected to witness the highest CAGR over the forecast period owing to factors such as, rising prevalence of infectious diseases, and availability of large patient pool
  • The North America peptide antibiotics market is growing steadily, driven by increasing demand for effective solutions to combat complex infections such as hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease
1.2.3. Route of Administration
1.2.4. Distribution channel
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product and disease outlook
2.2.2. Route of administration and distribution channel outlook
2.3. Competitive Insights
Chapter 3. Peptide Antibiotics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High prevalence of microbial resistance
3.2.1.2. Rising investment in R&D of novel drug
3.2.1.3. Technological advancement in peptide antibiotics
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment
3.2.2.2. Side-effects associated with drug
3.3. Peptide Antibiotics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Pipeline Analysis
Chapter 4. Peptide Antibiotics Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Peptide Antibiotics Market: Product Movement Analysis
4.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Product Revenue (USD Million)
4.4. Ribosomal Synthesized Peptide Antibiotics
4.4.1. Ribosomal synthesized peptide antibiotics market estimates and forecasts 2018 - 2030 (USD Million)
4.5. Non-ribosomal Synthesized Peptide Antibiotics
4.5.1. Non-ribosomal synthesized peptide antibiotics market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5. Peptide Antibiotics Market: Disease Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Peptide Antibiotics Market: Disease Movement Analysis
5.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Disease, Revenue (USD Million)
5.4. Skin Infection
5.4.1. Skin Infection market estimates and forecasts 2018 - 2030 (USD Million)
5.5. HABP/VABP
5.5.1. HABP/VABP market estimates and forecasts 2018 - 2030 (USD Million)
5.6. Blood Stream Infections
5.6.1. Blood Stream Infections market estimates and forecasts 2018 - 2030 (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6. Peptide Antibiotics Market: Route of Administration Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Peptide Antibiotics Market: Route of Administration Movement Analysis
6.3. Global Peptide Antibiotics Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
6.4. Oral
6.4.1. Oral market estimates and forecasts 2018 - 2030 (USD Million)
6.5. Injectable
6.5.1. Injectable market estimates and forecasts 2018 - 2030 (USD Million)
6.6. Topical
6.6.1. Topical market estimates and forecasts 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7. Peptide Antibiotics Market: Distribution Channel Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Peptide Antibiotics Market: Distribution Channel Movement Analysis
7.3. Global Peptide Antibiotics Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
7.4. Hospitals Pharmacies
7.4.1. Hospitals pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
7.6. Online Pharmacies
7.6.1. Online Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 8. Peptide Antibiotics Market: Regional Estimates & Trend Analysis By Product, Disease, Route of Administration, and Distribution Channel
8.1. Regional Dashboard
8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. Key company market share analysis, 2024
9.3.2. Pfizer Inc.
9.3.2.1. Company overview
9.3.2.2. Financial performance
9.3.2.3. Product benchmarking
9.3.2.4. Strategic initiatives
9.3.3. Teva Pharmaceuticals Industries Limited.
9.3.3.1. Company overview
9.3.3.2. Financial performance
9.3.3.3. Product benchmarking
9.3.3.4. Strategic initiatives
9.3.4. AbbVie Inc.
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Merck & Co., Inc.
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. The Menarini Group
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. Sanofi
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Eli Lilly and Company
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. GSK Plc.
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. NPS Pharmaceuticals
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Xellia Pharmaceuticals
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Product benchmarking
9.3.11.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 List of key distributors
Table 4 List of other companies
Table 5 List of key emerging company’s/technology disruptors/innovators
Table 6 North America Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
Table 7 North America Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 8 North America Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 9 North America Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 10 North America Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 11 U.S. Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 12 U.S. Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 13 U.S. Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 14 U.S. Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 15 Canada Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 16 Canada Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 17 Canada Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 18 Canada Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Mexico Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 20 Mexico Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 21 Mexico Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 22 Mexico Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 23 Europe Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
Table 24 Europe Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 25 Europe Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 26 Europe Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 27 Europe Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 28 U.K. Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 29 U.K. Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 30 UK Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 31 U.K. Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Germany Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 33 Germany Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 34 Germany Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 35 Germany Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 36 France Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 37 France Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 38 France Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 France Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 40 Spain Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 41 Spain Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 42 Spain Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 43 Spain Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 44 Italy Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 45 Italy Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 46 Italy Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 47 Italy Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 48 Denmark Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 49 Denmark Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 50 Denmark Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 51 Denmark Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 52 Sweden Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 53 Sweden Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 54 Sweden Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 55 Sweden Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 56 Norway Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 57 Norway Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 58 Norway Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 59 Norway Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 60 Asia Pacific Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 61 Asia Pacific Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 62 Asia Pacific Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 63 Asia Pacific Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 64 Japan Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 65 Japan Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 66 Japan Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 67 Japan Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 68 China Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 69 China Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 70 China Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 71 China Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 72 India Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 73 India Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 74 India Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 75 India Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 76 Australia Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 77 Australia Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 78 Australia Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 79 Australia Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 80 South Korea Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 81 South Korea Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 82 South Korea Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 83 South Korea Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 84 Thailand Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 85 Thailand Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 86 Thailand Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 87 Thailand Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 88 Latin America Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
Table 89 Latin America Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 90 Latin America Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 91 Latin America Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 92 Latin America Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 93 Brazil Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 94 Brazil Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 95 Brazil Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 96 Brazil Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 97 Argentina Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 98 Argentina Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 99 Argentina Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 100 Argentina Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 101 MEA Peptide Antibiotics Market, By Country, 2018 - 2030 (USD Million)
Table 102 MEA Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 103 MEA Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 104 MEA Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 105 MEA Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 106 South Africa Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 107 South Africa Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 108 South Africa Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 109 South Africa Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 111 Saudi Arabia Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 112 Saudi Arabia Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 114 UAE Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 115 UAE Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 116 UAE Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 117 UAE Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 118 Kuwait Peptide Antibiotics Market, By Product, 2018 - 2030 (USD Million)
Table 119 Kuwait Peptide Antibiotics Market, By Disease, 2018 - 2030 (USD Million)
Table 120 Kuwait Peptide Antibiotics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 121 Kuwait Peptide Antibiotics Market, By Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Peptide antibiotics market Segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Peptide antibiotics market snapshot
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook, revenue, 2024 (USD Million)
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Peptide Antibiotics market driver impact
Fig. 14 Peptide antibiotics market restraint impact
Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 16 Industry Analysis - Porter's Five Forces
Fig. 17 Peptide antibiotics market: Product outlook and key takeaways
Fig. 18 Peptide antibiotics market: Product movement analysis & market share 2024 & 2030
Fig. 19 Ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Non-ribosomal synthesized peptide antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Peptide Antibiotics market: Disease outlook and key takeaways
Fig. 22 Peptide Antibiotics market: Disease movement analysis & market share 2024 & 2030
Fig. 23 Skin infection market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 HABP/VABP market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Blood stream infections market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Peptide antibiotics market: Route of administration outlook and key takeaways
Fig. 28 Peptide antibiotics market: Route of administration movement analysis & market share 2024 & 2030
Fig. 29 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Peptide antibiotics market: Distribution channel outlook and key takeaways
Fig. 34 Peptide antibiotics market: Distribution channel movement analysis & market share 2024 & 2030
Fig. 35 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Global peptide antibiotics market: Regional movement analysis
Fig. 39 Global peptide antibiotics market: Regional outlook and key takeaways
Fig. 40 Global peptide antibiotics market share and leading players
Fig. 41 North America, by country
Fig. 42 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 U.S. key country dynamics
Fig. 44 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Canada key country dynamics
Fig. 46 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Mexico key country dynamics
Fig. 48 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 UK key country dynamics
Fig. 51 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Germany key country dynamics
Fig. 53 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 France key country dynamics
Fig. 55 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Italy key country dynamics
Fig. 57 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Spain key country dynamics
Fig. 59 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Denmark key country dynamics
Fig. 61 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Sweden key country dynamics
Fig. 63 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Norway key country dynamics
Fig. 65 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 China key country dynamics
Fig. 68 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Japan key country dynamics
Fig. 70 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 India key country dynamics
Fig. 72 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Thailand key country dynamics
Fig. 74 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 South Korea key country dynamics
Fig. 76 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Australia key country dynamics
Fig. 78 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Brazil key country dynamics
Fig. 81 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Argentina key country dynamics
Fig. 83 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 South Africa key country dynamics
Fig. 86 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Saudi Arabia key country dynamics
Fig. 88 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 UAE key country dynamics
Fig. 90 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Kuwait key country dynamics
Fig. 92 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Market share Analysis of key market players, 2024

Companies Mentioned

  • Pfizer Inc.
  • Teva Pharmaceuticals Industries Limited
  • AbbVie Inc.
  • Merck & Co., Inc.
  • The Menarini Group
  • Sanofi
  • Eli Lilly and Company
  • GSK Plc.
  • NPS Pharmaceuticals
  • Xellia Pharmaceuticals

Methodology

Loading
LOADING...

Table Information